Drug Profile
Anthrax vaccines - PaxVax
Alternative Names: Ad4-PA; Ad4-PA-1; Ad4-PA-Glycosylphosphatidylinositol; Ad4-PA-GPI; Ad4-PA-GPI-PaxVax; Ad4-PA-PaxVax; Adenovirus serotype 4 vector vaccine against anthrax protective antigen; Adenovirus-anthrax-vaccine-serotype-4-against-anthrax-PA-PaxVax; Adenovirus-anthrax-vector-candidate-vaccine-PaxVax; Adenovirus-serotype-4-anthrax-vector-candidate-vaccine-PaxVax; Adenovirus-serotype-4-protective-antigen-anthrax-vaccine-PaxVax; Anthrax-vaccine-PaxVaxLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PaxVax
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
- 28 Jul 2018 No recent reports of development identified for phase-I development in Anthrax(Prevention, In volunteers) in USA (PO, Capsule)
- 09 Mar 2016 Phase-I development is ongoing in USA